Therapeuticsmd Inc (TXMD) 6.67 $TXMD Therapeuti
Post# of 273242
Posted On: 09/19/2016 9:21:21 PM
Therapeuticsmd Inc (TXMD) 6.67 $TXMD
TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy(TM) (TX-004HR)
BusinessWire - Mon Sep 19, 3:30PM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced the acceptance of the NDA for Yuvvexy, the conditionally-approved trade name for TX-004HR, by the U.S. Food and Drug Administration (FDA). Yuvvexy is an investigational bio-identical 17B-estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar vaginal atrophy (VVA) in postmenopausal women.
TXMD: 6.67 (-0.08)
TherapeuticsMD Announces Second Quarter 2016 Financial Results
BusinessWire - Thu Aug 04, 3:05PM CDT
--- Topline phase 3 data for TX-001HR Replenish Trial on track for fourth quarter of 2016 -
TXMD: 6.67 (-0.08)
TherapeuticsMD Announces New Innovation in Compliance Packaging for Prenatal Vitamins
BusinessWire - Mon Jun 06, 5:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD) an innovative women's healthcare company and parent company of vitaMedMD(R), LLC ("vitaMedMD"
and BocaGreenMD(R), Inc. ("BocaGreenMD" , announced today an exciting new advancement in compliance packaging for prenatal vitamins that contain iron.
TXMD: 6.67 (-0.08)
TherapeuticsMD to Present at Two Upcoming Investor Conferences
BusinessWire - Fri Jun 03, 5:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company will participate in two upcoming investor conferences.
TXMD: 6.67 (-0.08)
What Those Drug Maker Majors Have That Investors Like? - Sanofi, TherapeuticsMD, Heron Therapeutics, and Rockwell Medical
PR Newswire - Tue May 31, 7:10AM CDT
The Major Drug Manufacturers industry continues to battle challenges in pricing, competition, and policies, but this has not slowed down a handful of stocks in this space from delivering remarkable results. Ahead of today's session, ActiveWallSt.com has issued technical alerts on the following Healthcare equities: Sanofi (NYSE: SNY), TherapeuticsMD Inc. (AMEX: TXMD), Heron Therapeutics Inc. (NASDAQ: HRTX), and Rockwell Medical Inc. (NASDAQ: RMTI). Learn how you can access the trading alerts for these stocks by clicking on the link below:
HRTX: 19.30 (+0.04), TXMD: 6.67 (-0.08), RMTI: 6.86 (+0.01), SNY: 38.70 (+0.27)
TherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial
BusinessWire - Sat May 14, 12:00PM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, presented additional secondary endpoint results from the pivotal phase 3 Rejoice Trial for its TX-004HR product candidate at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting held May 14-17, 2016, in Washington, DC.
TXMD: 6.67 (-0.08)
TherapeuticsMD Announces First Quarter 2016 Financial Results
BusinessWire - Tue May 03, 3:05PM CDT
--- Strong cash position of approximately $182 million to advance pipeline products -
TXMD: 6.67 (-0.08)
TherapeuticsMD to Host First Quarter 2016 Financial Results Conference Call and Webcast May 3
BusinessWire - Tue Apr 19, 3:20PM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that it will hold a conference call and live audio webcast to discuss first quarter 2016 financial and business results on Tuesday, May 3. The conference call and webcast will take place at 4:30 p.m. EDT. TherapeuticsMD Chief Executive Officer Robert G. Finizio and Chief Financial Officer Dan Cartwright will host the call.
TXMD: 6.67 (-0.08)
Drug Manufacturers - Major Equities Technical Updates -- TherapeuticsMD, Sanofi, Shire, and Novartis
ACCESSWIRE - Thu Feb 04, 7:04AM CST
NEW YORK, NY / ACCESSWIRE / February 04, 2016 / Park Lane Advisor has initiated coverage on the following equities: TherapeuticsMD Inc. (NYSE MKT: TXMD), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Novartis AG (NYSE: NVS). Free research report on TherapeuticsMD can be accessed at http://www.parklaneadvisor.com/ On Wednesday, February 03, 2016, the NASDAQ Composite ended at 4,504.24, down 0.28%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 16,336.66, and the S&P 500 closed at 1,912.53, up 0.50%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
TXMD: 6.67 (-0.08), SHPG: 203.44 (+2.84), SNY: 38.70 (+0.27), NVS: 79.94 (+0.60)
VitaMedMD unveils first certified vegan and kosher prescription prenatal multivitamin VitaTrue
M2 - Tue Jan 26, 4:53AM CST
Women's healthcare company TherapeuticsMD (NYSE MKT:TXMD) reported on Monday the immediate availability of the newest prescription prenatal multivitamin, vitaTrue.
TXMD: 6.67 (-0.08)
VitaMedMD Launches VitaTrue(TM), the First Certified Vegan and Kosher Prescription Prenatal Multivitamin
BusinessWire - Mon Jan 25, 3:05PM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD) ("TherapeuticsMD" or the "Company" , an innovative women's healthcare company and parent company of vitaMedMD, LLC ("vitaMedMD" , announced today the launch of vitaMedMD's newest prescription prenatal multivitamin, vitaTrue, adding to its successful prenatal line consisting of vitaPearl(TM), vitaMedMD One Rx, vitaMedMD Plus Rx, and vitaMedMD RediChew(TM) Rx.
TXMD: 6.67 (-0.08)
TherapeuticsMD to Present at Noble Financial Capital Markets' NobleCon12
BusinessWire - Wed Jan 13, 3:05PM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that Chief Executive Officer Robert G. Finizio will provide an overview of the company at the NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on January 19. The presentation is scheduled to begin at 10:30 a.m. EST.
TXMD: 6.67 (-0.08)
TherapeuticsMD concludes public offering at USD8.25 per share
M2 - Wed Jan 13, 4:57AM CST
Healthcare company TherapeuticsMD (NYSE MKT:TXMD) reported on Tuesday that it has completed a public offering of 17.4m shares of its common stock at a price of USD8.25 per share, before underwriting discounts and commissions.
TXMD: 6.67 (-0.08)
TherapeuticsMD Announces Closing of Common Stock Offering
BusinessWire - Tue Jan 12, 3:05PM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD) today announced the closing of its previously announced underwritten public offering of approximately 17.4 million shares of its common stock, which included shares sold pursuant to the underwriters' option to purchase up to an additional 15% of the shares of common stock initially offered, which option was exercised in full. The shares were offered to the public at a price of $8.25 per share, before underwriting discounts and commissions. At closing, TherapeuticsMD received gross proceeds from the offering of approximately $144 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were sold by TherapeuticsMD.
TXMD: 6.67 (-0.08)
TherapeuticsMD prices public offering at USD8.25 per share
M2 - Fri Jan 08, 6:35AM CST
Healthcare company TherapeuticsMD (NYSE MKT:TXMD) said on Thursday that it has priced a public offering of USD125m of shares of its common stock at USD8.25 per share.
TXMD: 6.67 (-0.08)
Why Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked Today
Brian Orelli, The Motley Fool - Motley Fool - Thu Jan 07, 2:08PM CST
What: At 2:30 p.m. EST, Epizyme is down 11%, Akebia Therapeutics is down 10%, and Cempra is down 11%. All three biotechs are down for the exact same reason: They sold additional shares through secondary offerings. So what: Companies...
TXMD: 6.67 (-0.08), IBB: 291.52 (-0.11), EPZM: 9.27 (-0.01), AKBA: 9.06 (+0.08), CEMP: 24.56 (-0.13)
TherapeuticsMD Announces Pricing of $125 Million Common Stock Offering
BusinessWire - Thu Jan 07, 5:45AM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD) today announced the pricing of an underwritten public offering of $125 million of shares of its common stock, offered at a price of $8.25 per share. The gross proceeds to TherapeuticsMD from this offering are expected to be approximately $125 million, before deducting underwriting discounts, commissions and other offering expenses payable by TherapeuticsMD. In addition, TherapeuticsMD has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to an additional 15% of the shares of common stock. All of the shares in the offering are to be sold by TherapeuticsMD. The offering is expected to close on or about January 12, 2016, subject to the satisfaction of customary closing conditions.
TXMD: 6.67 (-0.08)
Why TherapeuticsMD Inc. Is Tanking Today
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jan 06, 2:40PM CST
What: Shares of TherapeuticsMD , a drug manufacturer with a focus on women's health, were down by more than 10% as of 3:00 p.m ET Wednesday after news broke that the company was raising capital via a share offering. So what: The...
TXMD: 6.67 (-0.08), FBT: 99.44 (+0.16)
TherapeuticsMD begins public offering of USD125m common stock
M2 - Wed Jan 06, 5:20AM CST
Healthcare company TherapeuticsMD (NYSE MKT:TXMD) reported on Tuesday that it has started an underwritten public offering of USD125m of shares of its common stock.
TXMD: 6.67 (-0.08)
TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy(TM) (TX-004HR)
BusinessWire - Mon Sep 19, 3:30PM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced the acceptance of the NDA for Yuvvexy, the conditionally-approved trade name for TX-004HR, by the U.S. Food and Drug Administration (FDA). Yuvvexy is an investigational bio-identical 17B-estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar vaginal atrophy (VVA) in postmenopausal women.
TXMD: 6.67 (-0.08)
TherapeuticsMD Announces Second Quarter 2016 Financial Results
BusinessWire - Thu Aug 04, 3:05PM CDT
--- Topline phase 3 data for TX-001HR Replenish Trial on track for fourth quarter of 2016 -
TXMD: 6.67 (-0.08)
TherapeuticsMD Announces New Innovation in Compliance Packaging for Prenatal Vitamins
BusinessWire - Mon Jun 06, 5:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD) an innovative women's healthcare company and parent company of vitaMedMD(R), LLC ("vitaMedMD"
and BocaGreenMD(R), Inc. ("BocaGreenMD" , announced today an exciting new advancement in compliance packaging for prenatal vitamins that contain iron. TXMD: 6.67 (-0.08)
TherapeuticsMD to Present at Two Upcoming Investor Conferences
BusinessWire - Fri Jun 03, 5:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company will participate in two upcoming investor conferences.
TXMD: 6.67 (-0.08)
What Those Drug Maker Majors Have That Investors Like? - Sanofi, TherapeuticsMD, Heron Therapeutics, and Rockwell Medical
PR Newswire - Tue May 31, 7:10AM CDT
The Major Drug Manufacturers industry continues to battle challenges in pricing, competition, and policies, but this has not slowed down a handful of stocks in this space from delivering remarkable results. Ahead of today's session, ActiveWallSt.com has issued technical alerts on the following Healthcare equities: Sanofi (NYSE: SNY), TherapeuticsMD Inc. (AMEX: TXMD), Heron Therapeutics Inc. (NASDAQ: HRTX), and Rockwell Medical Inc. (NASDAQ: RMTI). Learn how you can access the trading alerts for these stocks by clicking on the link below:
HRTX: 19.30 (+0.04), TXMD: 6.67 (-0.08), RMTI: 6.86 (+0.01), SNY: 38.70 (+0.27)
TherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial
BusinessWire - Sat May 14, 12:00PM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, presented additional secondary endpoint results from the pivotal phase 3 Rejoice Trial for its TX-004HR product candidate at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting held May 14-17, 2016, in Washington, DC.
TXMD: 6.67 (-0.08)
TherapeuticsMD Announces First Quarter 2016 Financial Results
BusinessWire - Tue May 03, 3:05PM CDT
--- Strong cash position of approximately $182 million to advance pipeline products -
TXMD: 6.67 (-0.08)
TherapeuticsMD to Host First Quarter 2016 Financial Results Conference Call and Webcast May 3
BusinessWire - Tue Apr 19, 3:20PM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that it will hold a conference call and live audio webcast to discuss first quarter 2016 financial and business results on Tuesday, May 3. The conference call and webcast will take place at 4:30 p.m. EDT. TherapeuticsMD Chief Executive Officer Robert G. Finizio and Chief Financial Officer Dan Cartwright will host the call.
TXMD: 6.67 (-0.08)
Drug Manufacturers - Major Equities Technical Updates -- TherapeuticsMD, Sanofi, Shire, and Novartis
ACCESSWIRE - Thu Feb 04, 7:04AM CST
NEW YORK, NY / ACCESSWIRE / February 04, 2016 / Park Lane Advisor has initiated coverage on the following equities: TherapeuticsMD Inc. (NYSE MKT: TXMD), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Novartis AG (NYSE: NVS). Free research report on TherapeuticsMD can be accessed at http://www.parklaneadvisor.com/ On Wednesday, February 03, 2016, the NASDAQ Composite ended at 4,504.24, down 0.28%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 16,336.66, and the S&P 500 closed at 1,912.53, up 0.50%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
TXMD: 6.67 (-0.08), SHPG: 203.44 (+2.84), SNY: 38.70 (+0.27), NVS: 79.94 (+0.60)
VitaMedMD unveils first certified vegan and kosher prescription prenatal multivitamin VitaTrue
M2 - Tue Jan 26, 4:53AM CST
Women's healthcare company TherapeuticsMD (NYSE MKT:TXMD) reported on Monday the immediate availability of the newest prescription prenatal multivitamin, vitaTrue.
TXMD: 6.67 (-0.08)
VitaMedMD Launches VitaTrue(TM), the First Certified Vegan and Kosher Prescription Prenatal Multivitamin
BusinessWire - Mon Jan 25, 3:05PM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD) ("TherapeuticsMD" or the "Company"
, an innovative women's healthcare company and parent company of vitaMedMD, LLC ("vitaMedMD" , announced today the launch of vitaMedMD's newest prescription prenatal multivitamin, vitaTrue, adding to its successful prenatal line consisting of vitaPearl(TM), vitaMedMD One Rx, vitaMedMD Plus Rx, and vitaMedMD RediChew(TM) Rx. TXMD: 6.67 (-0.08)
TherapeuticsMD to Present at Noble Financial Capital Markets' NobleCon12
BusinessWire - Wed Jan 13, 3:05PM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that Chief Executive Officer Robert G. Finizio will provide an overview of the company at the NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on January 19. The presentation is scheduled to begin at 10:30 a.m. EST.
TXMD: 6.67 (-0.08)
TherapeuticsMD concludes public offering at USD8.25 per share
M2 - Wed Jan 13, 4:57AM CST
Healthcare company TherapeuticsMD (NYSE MKT:TXMD) reported on Tuesday that it has completed a public offering of 17.4m shares of its common stock at a price of USD8.25 per share, before underwriting discounts and commissions.
TXMD: 6.67 (-0.08)
TherapeuticsMD Announces Closing of Common Stock Offering
BusinessWire - Tue Jan 12, 3:05PM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD) today announced the closing of its previously announced underwritten public offering of approximately 17.4 million shares of its common stock, which included shares sold pursuant to the underwriters' option to purchase up to an additional 15% of the shares of common stock initially offered, which option was exercised in full. The shares were offered to the public at a price of $8.25 per share, before underwriting discounts and commissions. At closing, TherapeuticsMD received gross proceeds from the offering of approximately $144 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were sold by TherapeuticsMD.
TXMD: 6.67 (-0.08)
TherapeuticsMD prices public offering at USD8.25 per share
M2 - Fri Jan 08, 6:35AM CST
Healthcare company TherapeuticsMD (NYSE MKT:TXMD) said on Thursday that it has priced a public offering of USD125m of shares of its common stock at USD8.25 per share.
TXMD: 6.67 (-0.08)
Why Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked Today
Brian Orelli, The Motley Fool - Motley Fool - Thu Jan 07, 2:08PM CST
What: At 2:30 p.m. EST, Epizyme is down 11%, Akebia Therapeutics is down 10%, and Cempra is down 11%. All three biotechs are down for the exact same reason: They sold additional shares through secondary offerings. So what: Companies...
TXMD: 6.67 (-0.08), IBB: 291.52 (-0.11), EPZM: 9.27 (-0.01), AKBA: 9.06 (+0.08), CEMP: 24.56 (-0.13)
TherapeuticsMD Announces Pricing of $125 Million Common Stock Offering
BusinessWire - Thu Jan 07, 5:45AM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD) today announced the pricing of an underwritten public offering of $125 million of shares of its common stock, offered at a price of $8.25 per share. The gross proceeds to TherapeuticsMD from this offering are expected to be approximately $125 million, before deducting underwriting discounts, commissions and other offering expenses payable by TherapeuticsMD. In addition, TherapeuticsMD has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to an additional 15% of the shares of common stock. All of the shares in the offering are to be sold by TherapeuticsMD. The offering is expected to close on or about January 12, 2016, subject to the satisfaction of customary closing conditions.
TXMD: 6.67 (-0.08)
Why TherapeuticsMD Inc. Is Tanking Today
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jan 06, 2:40PM CST
What: Shares of TherapeuticsMD , a drug manufacturer with a focus on women's health, were down by more than 10% as of 3:00 p.m ET Wednesday after news broke that the company was raising capital via a share offering. So what: The...
TXMD: 6.67 (-0.08), FBT: 99.44 (+0.16)
TherapeuticsMD begins public offering of USD125m common stock
M2 - Wed Jan 06, 5:20AM CST
Healthcare company TherapeuticsMD (NYSE MKT:TXMD) reported on Tuesday that it has started an underwritten public offering of USD125m of shares of its common stock.
TXMD: 6.67 (-0.08)
(0)
(0)Scroll down for more posts ▼